Table 1.
The role of exosomal miRNAs in the pathogenesis of OA
| miRNAs | Sample | Exosome source | Role | Reference |
|---|---|---|---|---|
| miR‐95‐5p | Human | Chondrocytes | Enhances chondrogenesis and prevents the development of OA by directly targeting HDAC2/8 | 50 |
| miR-449a-5p | Human | OA chondrocytes | Inhibits ATG4B and autophagy in macrophages | 75 |
| miR-140-5p | Human | Synovial MSCs | Enhances the proliferation, migration of articular chondrocytes, and prevents OA in a rat model | 76 |
| miR-100-5p | Human | Infrapatellar fat pad MSCs | Ameliorates the OA degeneration by targeting the mTOR-autophagy pathway | 77 |
| miR-135b | Rats | MSCs | Promotes C5.18 cell (rat chondrocyte cell line) proliferation by regulating Sp1 | 82 |
| miR-92a-3p | Human | MSCs | Enhances chondrogenesis and suppresses cartilage degradation by targeting WNT5A | 84 |
| miR‐100‐5p | Human | Human umbilical cord MSCs | Inhibits cyclic strain‐induced ROS production and apoptosis in chondrocytes by targeting NOX4 | 97 |
| miR-126-3p | Rats | Synovial fibroblasts | Promotes chondrocyte proliferation and suppresses apoptosis by constraining chondrocyte inflammation | 113 |
| miR-135b | Rats | Bone marrow-derived MSCs | Attenuates cartilage injury by promoting synovial macrophage M2 polarization by targeting MAPK6 | 123 |
| miR-136-5p | Human | Bone marrow-derived MSCs | Inhibits chondrocyte degeneration in OA by targeting ELF3 | 158 |
| miR-9-5p | Rats | Bone marrow-derived MSCs | Alleviates OA degeneration by targeting SDC1 in an OA rat model | 159 |
| miR-140-5p | Human | Dental pulp stem cells | Inhibits IL-1β-induced chondrocyte apoptosis | 161 |
| miR-140 | Rats | Dendritic cells | Alleviates OA progression in a rat model | 162 |
| miR-140-5p | Human | Urine-derived stem cells | Inhibits the progression of KOA by mediating VEGFA | 165 |
| miR-320c | Human | Bone MSCs | Promotes chondrogenic differentiation | 166 |
| miR-26a-5p | Human | Bone MSCs | Alleviates OA via downregulation of PTGS2 | 167 |
| miR-372-3p | Human | OA chondrocytes | Promotes chondrocyte proliferation and inhibits apoptosis | 168 |
| miR-127-3p | Rats | Bone marrow-derived MSCs | Alleviates OA by regulating the CDH11-mediated Wnt/β-catenin pathway | 169 |
| miR-206 | Mice | Bone marrow-derived MSCs | Promotes proliferation and differentiation of osteoblasts in OA by reducing ELF3 | 170 |
| miR-147b | Human | MSCs treated with IL-1β and TNF-a | Inhibits the inflammatory response of OA SW982 cells (Synovial cell line) | 171 |
| miR-129-5p | Human | Synovial MSCs | Relieves IL-1β induced OA by targeting HMGB1 | 172 |
| miR-361-5p | Human | Bone MSCs | Alleviates OA by targeting DDX20 and NF-κB signaling pathway | 173 |
| miR-193b-3p | Human | Plasma | As a marker to distinguish expression levels between normal and OA patients | 174 |
OA osteoarthritis, MSCs mesenchymal stem cells, HDAC histone deacetylase, SOX9 SRY-box transcription factor 9, Sp1 specificity protein-1, ATG4B autophagy-related 4B, VEGFA vascular endothelial growth factor A, MAPK6 mitogen-activated protein kinase 6, mTOR mechanistic target of rapamycin, SDC1 syndecan-1, PTGS2 prostaglandin-endoperoxide synthase 2, CDH1 cadherin-11, ROS reactive oxygen species, NOX4 NADPH oxidase 4, HMGB1 high mobility group protein B1, DDX20 Asp-Glu-Ala-Asp-box polypeptide 20, NF-κB nuclear factor kappa-B